罗沙司他胶囊对初始腹膜透析患者贫血铁代谢的临床观察

Clinical Observation of Roxadustat Capsule on Iron Metabolism of Anemia in Patients with Initial Peritoneal Dialysis

目的:探讨罗沙司他胶囊联合多糖铁复合物胶囊对初始腹膜透析患者铁代谢的影响。方法:选择2020年9月至2021年9月海南医学院第二附属医院收治初始腹膜透析肾性贫血患者70例,随机分成观察组35例及对照组35例。观察组采用罗沙司他治疗,对照组采用重组人促红细胞生成素治疗,两组均联合多糖铁复合物治疗,连续治疗12周,采用重复测量方差分析和T检验对比两组患者治疗前及治疗4周、8周、12周贫血、铁代谢等相关指标变化;结果:两组患者的一般基线临床资料及一般临床生化资料无明显差异(P > 0.05);随着时间延长,两组患者RBC、HB、HCT水平均有不同程度升高(P < 0.01),观察组较对照组明显升高,且幅度相差增大(P < 0.01),两组间相比差异有统计学意义(P < 0.01)。随着时间延长,观察组患者TIBC、Tf水平显著升高(P < 0.01)与SF显著下降(P < 0.01),且幅度与对照组相差增大(P < 0.01),两组间相比差异有统计学意义(P < 0.01)。结论:与重组人促红细胞生成素相比,罗沙司他联合多糖铁复合物治疗肾性贫血能明显提高血红蛋白水平,改善铁代谢具有较好的疗效。

Objective: To investigate the effect of roxadustat capsule combined with iron polysaccharide com-plex capsules on iron metabolism in initial peritoneal dialysis patients. Methods: From September 2020 to September 2021, 70 patients with initial peritoneal dialysis renal anemia admitted to the Second Affiliated Hospital of Hainan Medical University were randomly divided into observation group with 35 cases and control group with 35 cases. The observation group was treated with roxadustat, while the control group was treated with recombinant human erythropoietin. Both groups were treated with iron polysaccharide complex capsules for 12 weeks. Repeated measure-ment analysis of variance and T-test were used to compare the changes of anemia, iron metabolism and other related indicators before treatment and 4, 8 and 12 weeks after treatment. Results: The general baseline clinical data and general clinical biochemical data were not significantly different between the two groups (P > 0.05). With the extension of experiment time, RBC, HB and HCT levels in both groups were increased in different degrees (P < 0.01). The observation group was signifi-cantly higher than the control group, and the amplitude difference was increased (P < 0.01). The difference between the two groups was statistically significant (P < 0.01). With the extension of ex-periment time, the levels of TIBC and Tf were significantly increased (P < 0.01) and SF was signifi-cantly decreased (P < 0.01) in the observation group. The difference between the observation group and the control group increased (P < 0.01), and the difference between the two groups was statisti-cally significant (P < 0.01). Conclusion: Compared with recombinant human erythropoietin, roxadu-stat combined with iron polysaccharide complex capsules can significantly improve the level of he-moglobin and iron metabolism in the treatment of renal anemia.